Stock 600332 GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Shanghai S.E.

Equities

600332

CNE000001733

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 29/04/2024 BST 		5-day change 1st Jan Change
32.08 CNY +0.82% Intraday chart for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited +2.95% +12.17%
04-26 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-18 Baiyunshan Pharmaceutical's 2023 Profit Rises 2% MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • Its low valuation, with P/E ratio at 8.57 and 8.24 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.19 for the 2024 fiscal year.
  • Sales forecast by analysts have been recently revised upwards.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED Stock Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
+12.17% 6.83B -
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
A+
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
C+
PFIZER, INC. Stock Pfizer, Inc.
-3.40% 157B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 874 Stock
  4. 600332 Stock
  5. Ratings Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited